A shareholder sent me this.. REGARDING ROPREN APPROVAL, THE ONLY TIMEFRAMES THAT HAVE been COMMUNICATED HAVE BEEN THOSE THAT WE WERE ADVISED WOULD BE MET BY THE AUTHORITIES INVOLVED. THE LATEST DELAY AROSE AS ............. - THE MOST INCONVENIENT TIME POSSIBLE FOR US. THAT DELAY THEN MEANT WE THEN GOT MIXED UP IN A LABORATORY RELOCATION , WHICH APPEARS TO HAVE COMPOUNDED THE SITUATION. AT THE END OF THE DAY, WE ARE ONLY TALKING ABOUT A SLIPPAGE OF A MONTH OR SO. GIVEN THAT WE WILL GET OVER THE LINE IN 3.5 YEARS COMPARED WITH THE NORMAL EXPECTATION OF 10-13 YEARS, IT IS NOT BAD.
WE HAVE MANY DEALS / INITIATIVES / ACTIVITIES ON THE GO AT THE MOMENT. IF WE WERE TO COMMUNICATE IT ALL, NO ONE WOULD BELIEVE THAT SUCH A SMALL TEAM COULD ACCOMPLISH SO MUCH. WE COULD EASILY HAVE CLOSED ON A NUMBER OF THESE DEALS WEEKS OR EVEN MONTHS AGO. BUT WE HAVE A RESPONSIBILITY TO ACT IN THE LONG TERM BEST INTEREST OF SHAREHOLDERS, NOT THE SHORT TERM BEST INTEREST OF SHARE TRADERS. THAT MEANS MAXIMISING THE LONG TERM CASH FLOW FROM AND VALUE OF SOLAGRAN. QUITE SIMPLY, WE WILL NOT ENTER INTO A DEAL UNLESS IT IS ABSOLUTELY ON THE RIGHT TERMS FOR SOLAGRAN.
No cap raising as suggested by the resident soap dropper. Adenovirus/childers flu ............. AT THE AGM. I BELIEVE ..... MADE IT CLEAR THAT IT WAS ONLY BECAUSE OF AN EXTRAORDINARY LEVEL OF CONFIDENCE IN THE EFFICACY AND THE SAFETY OF ROPREN ON THE PART OF THE SCIENTISTS RESPONSIBLE FOR THIS TRIAL THAT THEY WERE PREPARED TO EMBARK ON A TRIAL WITH CHILDREN USING A SUBSTANCE THAT HAD NOT ALREADY BEEN REGISTERED AS A PHARMACEUTICAL. THE RESULTS OF THIS TRIAL WILL NOT BE PASSED TO US UNTIL AFTER ROPREN IS REGISTERED then come the further announcements and SP climb...
SLA Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
